Vivos Therapeutics Inc <VVOS.OQ> expected to post a loss of 40 cents a share - Earnings Preview
Vivos Therapeutics Inc VVOS.OQ VVOS.O is expected to show a rise in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025
The Littleton Colorado-based company is expected to report a 7.2% increase in revenue to $3.667 million from $3.42 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Vivos Therapeutics Inc is for a loss of 40 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vivos Therapeutics Inc is $5.85, above its last closing price of $2.84.
This summary was machine generated May 9 at 16:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Understanding the U.S. Fiscal Framework: Is Trump’s Tariff-for-Tax-Cut Strategy Viable?
TradingKey – With the U.S. Senate and House of Representatives passing the budget resolution for President Donald Trump's second administration (Trump 2.0), his fiscal blueprint—centered on tax cuts, slashing government spending, and debt reduction—is moving forward. However, with federal debt at...
Will the New Taiwan Dollar’s Surge Continue? Likely Not!
TradingKey - Recent internal and external factors have driven a sharp appreciation of the New Taiwan Dollar (TWD). Looking ahead, despite potential pressure from the U.S., Taiwan’s export-oriented economy, emerging economic weakness, and China’s monetary easing ....jpg)
[IN-DEPTH ANALYSIS] Eurozone: EUR/USD Short-Term Outlook – One Word "Rise"; Two Words "Keep Rising"; Three Words "Continue to Rise"
TradingKey - In the short term (0-3 months), the EUR/USD exchange rate is expected to rise, primarily driven by developments on the USD side.
TSMC 2025 Q1 Outlook: AI-Driven Growth and Supply Chain Breakthrough Amid Tariff Pressures
As the world's leading semiconductor foundry, TSMC's Q1 2025 revenue reached NT$839.254 billion, a year-on-year increase of 41.6%, exceeding market expectations and in line with the company's guidance of NT$820 billion to NT$846.24 billion.
